RxDoctor Payments Data

Hanna Marrett

Nurse Practitioner · New Bern, NCNPI 1679567978

Payments from drug & device makers

$4,323in general payments, 2019–2025

Across 251 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$620
  • Otsuka America Pharmaceutical, Inc.$616
  • Teva Pharmaceuticals USA, Inc.$443
  • Sunovion Pharmaceuticals Inc.$434
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$409
  • Johnson & Johnson$321
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$4,323100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,323 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$18,058
Medicare patients
57
Services billed
244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate74$212,294
Abilify MaintenaAripiprazole39$114,135
Risperdal ConstaRisperidone Microspheres26$39,354
VraylarCariprazine Hcl27$38,545
Risperidone ErRisperidone Microspheres12$23,173
NuedextaDextromethorphan Hbr/Quinidine18$20,739
RexultiBrexpiprazole11$18,577
Lurasidone Hcl89$5,052
Quetiapine Fumarate ErQuetiapine Fumarate90$4,074
Aripiprazole99$3,903
Quetiapine Fumarate233$3,853
Hydroxyzine Hcl157$3,841
Paliperidone ErPaliperidone34$3,692
Focalin XrDexmethylphenidate Hcl11$2,376
Trazodone Hcl288$1,925

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$321$251,647100 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$616$132,71250 claims
AbbVieVraylar$620$38,54527 claims
Avanir Pharmaceuticals, Inc.Nuedexta$21$20,73918 claims
Almatica Pharma LLCSertraline Hcl$82$1,063154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →